People
Governance Verdict: B+
Tenet earns a strong-but-not-pristine governance grade. The board is genuinely independent (11 of 12), the comp program is structurally sound and shareholders ratified it with 93% support, and there are no related-party transactions. The drag is pay quantum, an entrenched Chair/CEO combo at the top, and a 12-month insider record that is all sells, no buys.
Governance Grade
2025 Say-on-Pay Support
Independent Directors
▲ 12 of 12
Insider Open-Market Sells (LTM, $M)
— 0 Buys
The People Running This Company
A McKinsey-trained physician-CEO with one publicly traded board seat (his own), a deep operating bench, and a Chairman/CEO who took the top job in 2021 and was given an $18M retention package in January 2025 to lock him in through 2028. Capability is not the issue here. The issue is concentration of authority — Sutaria is Chair, CEO, and the only insider on the board.
CEO Stake (Mkt Value, $M)
CEO 2025 Total Comp ($M)
CEO 2025 Retention LTI ($M)
What matters for trust. Sutaria's resume is genuinely top-tier (UCSD MD, McKinsey senior partner specializing in healthcare delivery), and his 2021 takeover coincides with a portfolio repositioning that delivered the highest TSR in the four-name peer group over one, three, and five years. CFO Sun Park's pre-Tenet role at AmerisourceBergen Pharma Distribution gives him scale-finance credentials. COO Lisa Foo's promotion at age 35 — a former McKinsey associate partner with seven years inside Tenet — is unusually fast for a hospital chain and signals heavy CEO sponsorship of his own bench. The 2026 retention bonuses on Foo, Park, and Arnst (each clawback-able if they leave before May 2029) tell you the board sees concentrated key-person risk.
Watch: there is no clear successor designated outside the CEO. Foo at 35 is the most likely internal candidate, but the four-year retention horizon on Sutaria's 2025 LTI ties succession planning to 2029.
What They Get Paid
Pay is high in absolute dollars but tightly indexed to performance. Sutaria earned $43.1M in 2025 — a 75% jump driven by a one-time $7.2M retention RSU and a $10.8M retention PRSU layered on top of normal LTI. AIP funded at the 200% cap because Adjusted EBITDA ($4.566B) and Adjusted FCF less NCI ($1.842B) both hit maximum.
Is pay sensible? Yes, with caveats. The $149M "compensation actually paid" to Sutaria in 2025 reflects mark-to-market on equity awards as Tenet stock returned 497% cumulatively since end-2020 versus 148% for the S&P 500 Healthcare index — Tenet beat its peer group by 350 percentage points. The 2023 PRSUs vested at 225% of target because all three years hit maximum and the company ranked #1 against HCA, UHS, and CHS on three-year TSR. Pay genuinely tracks performance; the issue is level. The pay ratio of 1:711 is at the high end of large hospital operators, and the $4M special retention bonuses paid in May 2025 to Park, Arnst, and Foo (in addition to record AIP and equity) feel belt-and-suspenders given the ordinary LTI grants already vested.
Compensation governance positives: independent Meridian as comp consultant; anti-hedging and anti-pledging enforced; no excise tax gross-ups since 2012; Rule 10D-1 clawback policy; six-month delay (409A); 50% PRSU split for non-CEOs and 60% for CEO.
Are They Aligned?
This is where the picture gets nuanced. Tenet has solid structural alignment (high stock ownership requirements, anti-hedge/pledge, no related-party transactions), but the behavior in the past 12 months has been one-sided.
Ownership map
Float is widely held. No strategic or activist owns more than 12.5%. There is no founder, no promoter, no controlling shareholder. The 16 named officers and directors collectively own 849,233 shares — under 1% of the 87.6M outstanding. The two largest beneficial owners are passive index funds (Vanguard + BlackRock = 21.9%), which generally vote with management and ISS recommendations.
Insider buying versus selling
Open-Market Sells (LTM)
Open-Market Buys (LTM)
Gross Sell Value ($M)
Tax-Withheld on Vesting ($M)
One-sided tape. 35 open-market sales totaling $46.2M; zero open-market purchases. Sutaria himself sold 78,762 shares at $190–$192 in September 2025 (~$15M). Most NEO sales coincided with PRSU vesting in February 2026 at $230–$239, including Arnst dropping his direct holdings from ~32,000 to 12 shares (excluding RSUs) on March 9, 2026. Director Romo sold $5.6M as she retired from Southwest Airlines in April 2025.
The benign reading is portfolio diversification — Sutaria still holds 533,564 shares worth $106M and sat well above his 6x-base-salary requirement before and after his September sales. Officers used 10b5-1 plans, no Rule 10D pre-clearance issues are disclosed, and most "sells" by NEOs (March 2026) simply convert vested PRSUs into cash after the 225% payout. The unfavorable reading is that not a single director or officer has bought in the open market for over a year while the stock has gone from $159 to $239.
Dilution and grant burn
Total potential dilution under approved plans is ~10.8M shares against 87.6M outstanding — about 12.3% on a fully-loaded basis. RSUs reduce the 2019 plan reservoir at a 1.65x rate, which is shareholder-friendly. The company also repurchased 8.8M shares for $1.4B in 2025, meaning net share count fell. This is one of the strongest signals of capital-allocation alignment in the file: management is buying back stock at a faster pace than they are issuing it.
Related-party transactions
The proxy explicitly states "There were no 'related person' transactions that require disclosure under the SEC rules since the beginning of our last completed fiscal year." Joint-venture put/call structures with USPI partners are flagged as a risk factor in the 10-K (partner interests, exit rights, contractual put/calls), but no individual director or officer is named as a counterparty. The Sutaria employment agreement (Jan 2025) includes a non-compete covering only four named hospital competitors — narrower than typical — but this is a structural pay-package disclosure, not an RPT.
Skin-in-the-game scorecard
Skin-in-the-Game Score
▲ 10 of 10
6 of 10. Plus marks for: CEO at 71x base in stock, all NEOs in compliance with 6x/4x/2x ownership multiples, anti-pledge/anti-hedge enforced, $1.4B in buybacks, no related-party transactions, no founder concentration. Drag from: zero open-market insider buys, $46M of one-way insider selling over 12 months, and combined Chair/CEO concentrating influence.
Board Quality
This is genuinely a high-quality board. Eleven of twelve directors are independent. The four-committee structure (Audit, HR, Governance, QCE) is standard, all chairs are women or veterans of regulated industries, and all committee members are independent.
Board matrix
Skill heatmap
Strengths: three audit-committee financial experts (Romo ex-Southwest CFO, Lynch ex-KPMG financial-services leader, Fisher ex-Dallas Fed President). Cybersecurity coverage via Admiral Haney (ex-US Strategic Command). Healthcare delivery through Bierman (Owens & Minor CEO), FitzGerald (Cardinal Specialty), West (US Army Surgeon General), and Agarwala (a16z Bio+Health). Five-year third-party-facilitated board self-evaluation.
Weaknesses worth flagging:
Combined Chair/CEO with Senator Kerrey (82) as Lead Director. Kerrey has the formal duties (sets agendas, chairs executive sessions, talks to investors), but the structural separation many proxy advisors prefer is absent. Age and tenure skew. Five directors are 70+ (Kerrey 82, Fisher 77, Blunt 76, Bierman 73, Mark/Haney 70). Average tenure on incumbents is ~6 years, but Kerrey's effective tenure on Tenet's board reaches back to 2001 (with a brief gap), making him a 25-year fixture. Cybersecurity bench thin — only three directors flagged with cyber expertise for a healthcare-data-rich operator. Director Rusckowski's exit (Nov 2025) came with a discretionary modification to continue vesting his RSU grant (incremental fair value ~$255K). Not material, but a cosmetic favor that proxy advisors typically ding. Director Romo, Bierman, Fisher, Kerrey all sold significant stock in 2025 alongside the rest. Direct ownership remaining is healthy but trending lower.
The Verdict
Grade: B+. Tenet has a structurally clean, performance-linked compensation program; an 11-of-12 independent board with three audit financial experts and chairs who are competent and overwhelmingly female; no related-party transactions; anti-hedge and anti-pledge policies that are real and enforced; and a CEO with $106M of his own money in the stock. Capital allocation backs alignment — $1.4B repurchased in 2025 against ~$200M of equity issuance.
The strongest positives. Performance pays out only when peers are beaten — the 225% payout on the 2023 PRSUs required Adjusted EBITDA, FCF less NCI, and each one-year EPS hurdle to maximum, plus #1 TSR rank. 93% Say-on-Pay support is a real shareholder endorsement. Board refresh delivered six new independents since 2018.
The real concerns. Pay quantum at $43M for the CEO and $4M+ unbudgeted retention bonuses for three NEOs in May 2025 sit on top of an already-record AIP. Twelve months of insider activity is all sells, no buys — $46M out the door versus zero in. The combined Chair/CEO arrangement with Sutaria leaves only Senator Kerrey as the formal counterweight, and Kerrey is 82.
What would move the grade. Up to A-: a meaningful open-market insider purchase, formal separation of Chair and CEO when Sutaria's contract expires in 2028, or termination of the special retention bonus practice. Down to B: renewed insider selling at a comparable pace through 2026, a related-party transaction emerging at the next proxy cycle, or any compliance event under the QCE Committee's purview. The history of Tenet (the 2016 $513M Atlanta DOJ settlement, predating current management by half a decade) sets the bar for what "ethics oversight" has to mean here — and so far Sutaria's tenure has run clean.